Patrick J McEnany, Board Member at Catalyst Pharmaceuticals CPRX, reported an insider sell on November 13, according to a new SEC filing. Tracking the Thursday's morning session, Catalyst ...

Truist Financial analyst Joon Lee reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...

Catalyst Pharmaceuticals Inc (CPRX) reports a 25.3% increase in total revenue and updates its full-year guidance, while ...

Oppenheimer analyst Leland Gershell maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Thank you for standing by. My name is Kris and I will be your ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse ...

Another notable valuation metric for CPRX is its P/B ratio of 4.26. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

A team of AI researchers and mathematicians affiliated with several institutions in the U.S. and the U.K. has developed a math benchmark that allows scientists to test the ability of AI systems to ...

Catalyst Pharmaceuticals ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.

Have you been paying attention to shares of Corcept Therapeutics (CORT)? Shares have been on the move with the stock up 12.1% over the past month. The stock hit a new 52-week high of $51.32 in the ...

State of Alaska Department of Revenue decreased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 3.4% in the third quarter, Holdings Channel reports. The fund owned 63,666 ...